Analysis of the impact of bariatric surgery on medium-term pharmacological expenditure.

INTRODUCTION: Obesity and associated diseases represent an important health and economic problem since pharmacological treatment for many of these pathologies needs lifelong subsidies. Theoretically, bariatric and metabolic surgery decreases the medication requirements of patients for these diseases but may result in other types of pharmacological needs. This study aims to demonstrate whether there is a real decrease in pharmacological expenditure after bariatric surgery. MATERIAL AND METHODS: Retrospective cross-sectional analysis of patients who were treated in our centre between 2012 and 2016, comparing different associated comorbidities and pharmacological expenses one month before and 2 years after surgery. RESULTS: 400 patients were operated. The results were presented, showing the differences between the resolution of the different comorbidities and the pharmacological savings generated for each of the surgical techniques studied. The most cost-effective comorbidity in the study was type 2 diabetes mellitus (DM2). The surgical technique with the best results was metabolic bypass, presenting a cost difference after surgery of 507 euros per month (P < 0.001). CONCLUSIONS: In a 2-year follow-up after bariatric surgery, a decreased prevalence of obesity-related diseases and associated pharmacological expenditure was observed, showing the efficiency of this intervention over the medium term.

Analysis of the impact of bariatric surgery on medium-term pharmacological expenditure. / Análisis del impacto de la cirugía bariátrica en el gasto farmacológico a medio plazo.

INTRODUCTION: Obesity and associated diseases represent an important health and economic problem since pharmacological treatment for many of these pathologies needs lifelong subsidies. Theoretically, bariatric and metabolic surgery decreases the medication requirements of patients for these diseases but may result in other types of pharmacological needs. This study aims to demonstrate whether there is a real decrease in pharmacological expenditure after bariatric surgery. MATERIAL AND METHODS: Retrospective cross-sectional analysis of patients who were treated in our centre between 2012 and 2016, comparing different associated comorbidities and pharmacological expenses one month before and 2years after surgery. RESULTS: 400 patients were operated. The results were presented, showing the differences between the resolution of the different comorbidities and the pharmacological savings generated for each of the surgical techniques studied. The most cost-effective comorbidity in the study was type2 diabetes mellitus (DM2). The surgical technique with the best results was metabolic bypass, presenting a cost difference after surgery of 507euros per month (P<.001). CONCLUSIONS: In a 2-year follow-up after bariatric surgery, a decreased prevalence of obesity-related diseases and associated pharmacological expenditure was observed, showing the efficiency of this intervention over the medium term.

Idiopathic granulomatous mastitis: A systematic review of 3060 patients.

Idiopathic granulomatous mastitis is a rare benign breast disease. A systematic review was designed. Clinical and therapeutic characteristics were analyzed. Human Development Index (HDI) was used to define two groups of study: group A (very high and high HDI) and group B (medium and low HDI). Corticosteroid therapy was done in 69% group A and 78% group B. Surgery was done in 63% in group A and 83% in group B. Antibiotics were used in 68% group A and 88% group B. There is no consensus about optimal treatment for granulomatous mastitis.

[Differential diagnosis and management of intramuscular myxomas: A review of our experience]. / Diagnóstico diferencial y manejo de mixomas intramusculares: revisión de nuestra experiencia.

BACKGROUND: Intramuscular myxoma is a rare benign soft tissue tumour of mesenchymal origin, which appears as a painless mass of slow growth. Early diagnosis is important in order to differentiate it from other entities, especially soft tissue sarcoma. CLINICAL CASES: Two cases, both women with a mean age of 52.5 years (range 40-65) are presented. The first was seen due to growth of a gluteal mass, and the second by coccydynia. Computed tomography and nuclear magnetic resonance were the diagnostic tests of choice. In one case, where there was a single but large lesion, radical extirpation of the gluteal muscle was chosen. In the other case, in which the lesions were multiple, individualised excision of cysts was performed. Postoperative functional limitation was low in both types of surgery, with good oncological results being obtained. CONCLUSION: Intramuscular myxomas are benign lesions. There are no cases of malignancy or recurrence due to incomplete resection. It has to be determined whether they are single or multiple, since in the latter case, they could be due to syndromes such as Mazabraud syndrome, which is associated with bone fibrous dysplasia, or Albright syndrome that is also associated with pigmented skin spots.

Rendimiento diagnóstico de la punción aspiración con aguja fina de tejido tiroideo / Diagnostic efficacy of fine needle aspiration of thyroid tissue

Introducción. La punción aspiración con aguja fina (PAAF) de la glándula tiroides constituye un proceso diagnóstico que permite determinar de forma segura y fiable, si un nódulo tiroideo es benigno o maligno. Objetivo. El objetivo del estudio fue evaluar la eficacia diagnóstica de la PAAF en nuestro centro. Material y métodos. Se llevó a cabo de 2009 a 2013 un estudio retrospectivo de pacientes con nódulo tiroideo sospechoso de ser maligno. Las variables del estudio fueron: edad, sexo, tamaño del nódulo tiroideo, realización de PAAF, estudio anatomo-patológico de la biopsia y diagnóstico definitivo. Se comparó el rendimiento diagnóstico de la PAAF frente a los resultados de la biopsia posoperatoria. Resultados. Durante los cinco años del estudio, se practicó PAAF de tejido tiroideo a 112 pacientes (30,2 %, hombres, y 69,8 %, mujeres), con un tamaño medio nodular de 2 cm (rango: 1 a 4). La PAAF fue positiva para neoplasia maligna en 26 casos (23,2 %) y negativa en 86 casos (76,8 %). Los resultados del rendimiento de la prueba fueron: sensibilidad de 45,5 % (intervalo de confianza 95 % [IC95%] 28,1-63,6), especificidad de 86,1 % (IC95% 76,5-92,8), valor predictivo positivo de 57,7 % (IC95% 36,9-76,6) y valor predictivo negativo de 79,1 % (IC95% 69-87,1). Conclusión. Tras este análisis, se obtiene un resultado malo con posibilidad de ser mediocre, por lo que habría que replantearse la utilidad de esta prueba invasiva en nuestro centro y la búsqueda de posibles errores.

Background: Thyroid fine needle aspiration (FNA) is a safe and reliable diagnostic procedure for determining if a thyroid nodule is benign or malignant. Objective: The objective of this study was to evaluate the efficacy of FNA diagnosed in our center. Material and methods: Retrospective study of patients with thyroid nodule suspicious for malignancy, in the period 2009 to 2013. The variables used in this study were: age, sex, size of thyroid nodule, FNA performance, pathology and definitive diagnosis. The diagnostic accuracy of FNA was compared with the results of postoperative biopsy. Results: During the 5-year study, FNA of thyroid tissue was performed at 112 patients (30.2% men and 69.8% women), with nodules of average size of 2 cm (range 1-4). FNA was positive for malignancy in 26 cases (23.2%) and negative in 86 cases (76.8%). The performance results of the test were: sensitivity 45.5% (confidence interval [CI] 95%: 28.1% -63.6%), specificity of 86.1% (95% CI: 76.5 % - 92.8%), positive predictive value of 57.7% (95% CI: 36.9% - 76.6%) and negative predictive value of 79.1% (95% CI: 69% - 87 1%) Conclusion: A bad result with the possibility of being mediocre is obtained with this analysis, which should rethink the usefulness of this invasive test in our center and search for possible errors.

Primary esophageal melanoma: report of a case.

INTRODUCTION: Primary malignant melanoma of the esophagus is a rare tumor representing only 0.1-0.2% of esophageal malignancies. The goal of the study was to report on the management of a new case diagnosed and treated in our site. CASE REPORT: A 67-year-old patient presented with dysphagia to solids with no other remarkable history or associated skin lesions. He underwent gastroscopy, which revealed a polypoid mass suggestive of neoplasm in the distal third of the esophagus. Biopsy indicated melanoma with positive immunohistochemical markers S100 and HMB45, and negative cytokeratins and CEA. Computerized tomography (CT) and positron-emission tomography (PET) scans showed no local infiltration or distant metastases. An Ivor-Lewis esophagectomy procedure was performed with regional lymphadenectomy. Postoperative stay lasted for three weeks, and no remarkable postsurgical complications arose. The pathological study of the specimen confirmed the diagnosis of primary esophageal melanoma. DISCUSSION: Primary malignant melanoma of the esophagus has an unfortunate prognosis as it is an aggressive tumor usually diagnosed at an advanced stage, with local invasion and metastatic disease. Currently, surgery is the treatment of choice, with the remaining adjuvant therapies obtaining limited results.

[Diagnostic yield of pancreatic percutaneous puncture depending on the size of the lesion]. / Rentabilidad diagnóstica de la punción percutánea pancreática en función del tamaño de la lesión.

INTRODUCTION: The aim of the present study was to study the diagnostic efficacy of the percutaneous puncture of pancreatic tissue. MATERIAL AND METHODS: A retrospective study was conducted on patients with suspicion of pancreatic neoplasm, and with a percutaneous biopsy of pancreatic tissue, from 2000 to 2011. For the statistical comparative analysis, the sample was stratified by tumour size: ≤ 3cm and > 3cm. RESULTS: A total of 90 biopsies were performed. Pancreatic neoplasm diagnosis was made in 47 cases (52%), with 16 false negatives (18%), no false positives, and chronic pancreatitis in 24 cases (27%). The efficacy of the test results were: an overall sensitivity of 75% (95% CI: 62%-85%), a specificity of 100% (95% CI: 87%-100%), a positive predictive value of 100% (95% CI: 92%-100%), and a negative predictive value of 63% (95% CI: 46%-77%). For tumour sizes ≤ 3cm the sensitivity was 70% (95% CI: 45%-88%), with a specificity of 100% (95% CI 66%-100%), a positive predictive value of 100% (95% CI: 76%-100%, and a negative predictive value 60% (95% CI: 32%-83%). For tumours greater than 3cm, the sensitivity was 88% (95% CI: 70%-98%), the specificity was 100% (95% CI: 75%-100%), with a positive predictive value of 100% (95% CI: 85%-100%) and a negative predictive value of 81% (95% CI: 54%-96%). CONCLUSIONS: Pancreatic percutaneous biopsy efficacy was strongly determined by lesion size. For tumour sizes less than 3cm, the sensitivity and negative predictive value are unacceptably low, as negative results would not reliable.